Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in overuse rotator-cuff tendinopathy
NCT03344640Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of secukinumab in rotator cuff tendinopathy (RCT), sponsored by Novartis. Started Dec 2017; status: completed.
02
Drugs
secukinumab
03
Conditions
rotator cuff tendinopathy (RCT)
Beyond the preview
Go deeper on NCT03344640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03344640.